Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/30255
Title: | Randomised comparison of a biodegradable polymer ultra-thin sirolimus-eluting stent versus a durable polymer everolimus-eluting stent in patients with de novo native coronary artery lesions: the meriT-V trial |
Authors: | ABIZAID, Alexandre; KEDEV, Sasko; KEDHI, Elvin; TALWAR, Suneel; ERGLIS, Andrejs; HLINOMAZ, Ota; MASOTTI, Monica; FATH-ORDOUBADI, Farzin; LEMOS, Pedro; MILEWSKI, Krzysztof; BOTELHO, Roberto; COSTA, Ricardo; BANGALORE, Sripal |
Citation: | EUROINTERVENTION, v.14, n.11, p.1207-1214, 2018 |
Abstract: | Aims: The aim of this study was to evaluate the safety and efficacy of the BioMime sirolimus-eluting coronary stem (SES) compared to the XIENCE family of everolimus-eluting coronary stents (EES) in the treatment of patients with de novo native coronary artery lesions. Methods and results: The meriT-V is a prospective, multicentre, randomised, open-label, active-controlled, non-inferiority trial. A total of 256 patients with up to two de novo native coronary artery lesions were enrolled and randomly assigned (2:1) to BioMime SES or XIENCE EES. BioMime SES was non-inferior to XIENCE EES for the primary endpoint of in-stent late lumen loss (0.15 +/- 0.27 mm vs. 0.15 +/- 0.29 mm; difference: -0.006 mm; 95% confidence interval: -0.085 to 0.072; p=0.87; p for non-inferiority <0.0001) at nine-month follow-up. The major adverse cardiac events rate was numerically lower in the BioMime SES group (2.98% vs. 7.14%; p=0.13), driven by a statistically significant lower risk of any myocardial infarction (0.60% vs. 4.76%; p=0.03), when compared with the XIENCE EES group. There was no difference in target vessel myocardial infarction (p=0.62) between the groups. There was no definite or probable stent thrombosis in either group. Conclusions: In the treatment of de novo native coronary artery lesions, the biodegradable polymer ultrathin SES (BioMime) was non-inferior to a durable polymer EES (XIENCE) at nine-month follow-up. Further studies powered for clinical endpoints are needed. |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - HC/InCor Artigos e Materiais de Revistas Científicas - LIM/11 Artigos e Materiais de Revistas Científicas - ODS/03 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_ABIZAID_Randomised_comparison_of_a_biodegradable_polymer_ultrathin_sirolimuseluting_2018.PDF Restricted Access | publishedVersion (English) | 667.58 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.